BioSpace News Archive

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Zentalis has initiated patient dosing in three new combination and monotherapy clinical trials:

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that it has completed enrollment earlier than expected in its MIRA-2 (NCT04620213) Phase 3 registration clinical trial evaluating the safety and efficacy of Nyxol®

Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin (Hb), today reported results from its Phase 2a clinical trial of IMR-687 in adult patients with sickle cell disease (SCD).

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, is pleased to announce the appointment of Ms. Maital Shemesh-Rasmussen, a global health-tech marketing strategist, and Mr. Rami Levi, a leader in global marketing and international governmental affairs, to its Board of Directors.

Dewpoint Therapeutics, the biomolecular condensates company, today announced a new research collaboration with Pfizer (NYSE: PFE) for the development of potential therapeutics for the treatment of myotonic dystrophy type 1, DM1, a rare genetic disorder and one of two types of myotonic dystrophy.

Biomarck Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company developing anti-inflammatory and oncological therapies that target the MARCKS protein, today announced the appointment of Dr. Graham G. Lumsden as President and Chief Executive Officer.

Orthofix Medical Inc. announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in two upcoming virtual investor conferences.

TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced that David Southwell, Chief Executive Officer, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that company management will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals Announces Participation at the 39 th Annual J.P. Morgan Healthcare Conference